Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1385-1389

  Bodnar, Lubomir ^a   Stec, R ^a   Cierniak, S ^a   Synowiec, A ^a   Wcislo G ^a   Jesiotr, M ^a   Koktysz, R ^a   Kozlowski W ^a   Szczylik, C ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

AKT; Everolimus; MTOR; PI3KCA; Renal cell carcinoma

Indexed keywords

CALCIUM; EVEROLIMUS; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY METASTASIS; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PI3KCA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FOLLOW UP; GENETICS; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84946735754     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv166     Document Type: Article

References (15)

1. Wysocki PJ. mTOR in renal cell cancer: modulator of tumour biology and therapeutic target. Expert Rev Mol Diagn 2009; 9: 231-241.
2. Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011; 6: 214-221.
3. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007; 109: 2257-2267.
4. Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumour progression:unlinking immunosuppression from anti-tumour efficacy. Transplantation 2002; 73: 1565-1572.
5. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
6. Common Terminology Criteria for Adverse Events version 3.0. http://ctep.cancer. gov/protocolDevelopment/electronic_applications/ctc.htm (11 April 2015, date last accessed).
7. McCarty KS, Jr, Miller LS, Cox EB et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
8. Schultz L, Chaux A, Albadine R et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 2011; 35: 1549-1556.
9. Li S, Kong Y, Si L et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer 2014; 14: 376.
10. Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674-1681.
11. Nawroth R, Stellwagen F, Schulz WA et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011; 6:e27509.
12. Hildebrandt MA, Yang H, Hung MC et al. Genetic variations in the PI3K/PTEN/AKT/ mTOR pathway are associated with clinical outcomes in oesophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009; 27: 857-871.
13. Gerlinger M, Rowan AJ, Horswell S et al. Intratumour heterogeneity and branched evolution revealed by multi-region sequencing. N Engl J Med 2012; 366:883-892.
14. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-4882.
15. Voss MH, Hakimi AA, Pham CG et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014; 20: 1955-1964.